{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:13:06Z","timestamp":1784157186139,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pityriasis rubra pilaris is a rare inflammatory papulosquamous skin disease without any approved treatment options. Variants in the <jats:italic>CARD14<\/jats:italic> (caspase recruitment domain family member 14) gene have been identified to play a role in the pathophysiology of atypical juvenile PRP by activating the IL-23\/IL-17A cytokine axis, highlighting this pathway as a potential target of therapy. Here, we present a case of successful treatment with ixekizumab, a humanized monoclonal anti-IL-17A antibody, in an atypical juvenile PRP (type V) patient with a novel variant of <jats:italic>CARD14<\/jats:italic> mutation.<\/jats:p>","DOI":"10.3389\/fmed.2025.1637045","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:20:38Z","timestamp":1753161638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with ixekizumab"],"prefix":"10.3389","volume":"12","author":[{"given":"Laura","family":"Millak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Volc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","article-title":"Pityriasis Rubra Pilaris.","volume":"5","author":"Griffiths","year":"1980","journal-title":"Clin Exp Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial Pityriasis Rubra Pilaris is caused by mutations in CARD14.","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-helper T cell 17 axis as a treatment target for Pityriasis Rubra Pilaris.","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jid.2024.04.036","article-title":"Hyperactivation of the IL-17 axis and IL-36 signaling in card14-mutant Pityriasis Rubra Pilaris mouse model.","volume":"145","author":"Yoshikawa","year":"2025","journal-title":"J Invest Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with Pityriasis Rubra Pilaris: a single-arm trial.","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2133.1996.d01-1114.x","article-title":"Pityriasis Rubra Pilaris and human immunodeficiency virus infection\u2013type 6 Pityriasis Rubra Pilaris?","volume":"135","author":"Misery","year":"1996","journal-title":"Br J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40257-017-0338-1","article-title":"A review on Pityriasis Rubra Pilaris.","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamadermatol.2016.3601","article-title":"Pityriasis Rubra Pilaris type V as an autoinflammatory disease by CARD14 mutations.","volume":"153","author":"Takeichi","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"E30890","DOI":"10.1097\/MD.0000000000030890","article-title":"Association between CARD14 gene polymorphisms and psoriasis vulgaris in Hainan Han population based on exon sequencing: a case-control study.","volume":"101","author":"Msafiri Makene","year":"2022","journal-title":"Medicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/jid.2015.288","article-title":"Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris.","volume":"135","author":"Berki","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","article-title":"CARD14 gain-of-function mutation alone is sufficient to drive IL-23\/IL-17-mediated psoriasiform skin inflammation in vivo.","volume":"138","author":"Mellett","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eado2365","DOI":"10.1126\/sciadv.ado2365","article-title":"Targeting IL-1 controls refractory Pityriasis Rubra Pilaris.","volume":"10","author":"Schmauch","year":"2024","journal-title":"Sci Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/J.JAAD.2018.02.034","article-title":"CARD14 \u2013 associated papulosquamous eruption (CAPE): a spectrum including features of psoriasis and Pityriasis Rubra pilaris.","volume":"79","author":"Craiglow","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/CUP.13633","article-title":"Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.","volume":"47","author":"Ring","year":"2020","journal-title":"J Cutan Pathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40272-022-00549-4","article-title":"Treatment options for juvenile Pityriasis Rubra Pilaris.","volume":"25","author":"Guenther","year":"2023","journal-title":"Paediatr Drugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1360248","DOI":"10.3389\/fmed.2024.1360248","article-title":"Case report: successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation.","volume":"11","author":"Nied\u017awied\u017a","year":"2024","journal-title":"Front. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14097","DOI":"10.1111\/dth.14097","article-title":"Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) Pityriasis Rubra Pilaris: a case report and literature review.","volume":"33","author":"Liang","year":"2020","journal-title":"Dermatol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.21708","article-title":"Secukinumab for the treatment of adult-onset Pityriasis Rubra Pilaris: a single-arm clinical trial with transcriptomic analysis.","volume":"187","author":"Boudreaux","year":"2022","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.21229","article-title":"Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.","volume":"187","author":"Klein","year":"2022","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ced\/llae019","article-title":"A novel variant with a severe phenotype in a patient with CARD14-associated papulosquamous eruption successfully treated with ixekizumab.","volume":"49","author":"Ouyang","year":"2024","journal-title":"Clin Exp Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","article-title":"Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial.","volume":"158","author":"Paller","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/pde.15700","article-title":"Rapid clearance of extensive juvenile Pityriasis Rubra Pilaris with ixekizumab.","volume":"41","author":"Kim","year":"2024","journal-title":"Pediatr Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/JDV.15455","article-title":"The management and genetic background of Pityriasis Rubra Pilaris: a single-centre experience.","volume":"33","author":"G\u00e1l","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1637045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:20:39Z","timestamp":1753161639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1637045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":23,"alternative-id":["10.3389\/fmed.2025.1637045"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1637045","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1637045"}}